Avenue Biosciences funding news – Helsinki-based Avenue BiosciencesSecures $2.5Million in Seed Funding

Investors of this Round

This round was led by Voima Ventures with additional participation from Inventure and US angel investors.

Funding Utilisation

The funding will accelerate the development of Avenue Biosciences platform designed to improve the efficiency of protein production in the biopharmaceutical industry.

The technology promises to shorten development times and lower costs for critical therapies, making treatments such as monoclonal antibodies, synthetic proteins, gene therapies and mRNA-based therapies more accessible to patients globally. By addressing one of biotech’s biggest challenges, efficient and scalable protein production, Avenue Biosciences platform will transform the speed of life-saving therapies being brought to market.

Tero-Pekka Alastalo, CEO of Avenue Biosciences said, "The potential for impact is Huge, With this platform, we are not only optimizing the production process but enabling faster access to therapies that could significantly change patients’ lives."

Avenue Biosciences Offering

Avenue’s proprietary technology screens and optimizes signal peptides, the key to guiding protein delivery within cells, using machine learning to enhance efficiency.

The company is poised to launch commercial sales of the platform in Q4, which will further fuel the development of life-changing therapies. With operations based in Helsinki and a strategic headquarters in San Francisco, Avenue is positioned to tap into both Nordic expertise and North American markets, driving growth in the EU and beyond.

Founding story: Avenue Biosciences

Avenue Biosciences was born from years of research at theUniversity of Helsinki. Founded by Research Director Ville Paavilainen and CEO Tero-Pekka Alastalo, who first collaborated during their post-doctoral work at Stanford and UCSF, the company brings together a team of experts. Joined by co-founders COO Katja Rosti and CSO Juho Kellosalo, the leadership team is out to solve one of biotechnology’s biggest challengesscalable and efficient protein production.

Jenny Engerfelt - Voima Ventures Partner "This technology taps into a rapidly expanding biopharmaceutical market and poised for substantial growth. By making the production of complex proteins more efficient and affordable, it not only accelerates the development of innovative treatments but also significantly enhances the commercial scalability of these therapies. This positions us to capture significant value while improving access to life-saving medicines across a wider range of diseases."

Tuomas Kosonen - Inventure Partner “Their innovative approach to a persistent bottleneck in protein production has the potential to disrupt the biopharmaceutical industry.We are especially excited to support Tero-Pekka for the second time as the teamworks towards realizing the full potential of their technology.”

About Avenue Biosciences

Avenue Biosciences is a biotechnology company dedicated to accelerating the discovery and development of protein biologics, so that no life-saving therapy goes unrealized because of production barriers. Headquartered in San Francisco, USA, and with laboratory operations in Helsinki, Finland, Avenue Biosciences has developed a protein engineering platform that combines organic biologics and machine learning to boost protein production.

Read also - Oriole Networks funding news – London-based Oriole Networks Secures an Additional €20.2 Million Funding